Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRMT5 | O14744 | 10/20 | 0.38 |
| ▸ | WDR77 | Q9BQA1 | 10/20 | 0.38 |
| ▸ | IDO1 | P14902 | 1/20 | 0.34 |
| ▸ | PIK3CD | O00329 | 4/20 | 0.34 |
| ▸ | PIK3CA | P42336 | 4/20 | 0.34 |
| ▸ | RORC | P51449 | 2/20 | 0.34 |
| ▸ | PRKCA | P17252 | 1/20 | 0.34 |
| ▸ | MMP12 | P39900 | 1/20 | 0.34 |
| ▸ | GAA | P10253 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL792849 | 0.90 | PIK3CD (0.35) | PRMT5WDR77IDO1PIK3CDPIK3CA | |
| SCHEMBL772620 | 0.88 | PRKCA (0.46) | PRMT5WDR77PIK3CDPIK3CAPRKCA | |
| SCHEMBL771886 | 0.86 | NR1I2 (0.39) | PRKCAMMP12GAASMN1; SMN2 | |
| SCHEMBL792719 | 0.80 | DRD1 (0.39) | PRKCAMMP12GAASMN1; SMN2 | |
| SCHEMBL771540 | 0.73 | PRKCA (0.46) | PRMT5WDR77PIK3CDPIK3CAPRKCA | |
| SCHEMBL792656 | 0.73 | PRMT5 (0.39) | PRMT5WDR77PIK3CDPIK3CAPRKCA | |
| SCHEMBL772111 | 0.72 | PRKCA (0.44) | PRMT5WDR77PIK3CAPRKCAMMP12 | |
| SCHEMBL792848 | 0.72 | ROCK1 (0.42) | PRKCAMMP12 | |
| SCHEMBL772448 | 0.71 | PRKCA (0.48) | PRMT5WDR77PIK3CDPIK3CAPRKCA | |
| SCHEMBL13286226 | 0.71 | PRKCA (0.43) | PRMT5WDR77PRKCAMMP12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120070409-A1 | TETRACYCLIC FUSED HETEROCYCLIC COMPOUND AND USE THEREOF AS HCV POLYMERASE INHIBITOR | JAPAN TOBACCO INC. (JP) | 2012-03-22 | — | — | US | disclosed |
| US-7977331-B1 | Tetracyclic fused heterocyclic compound and use thereof as HCV polymerase inhibitor | JAPAN TOBACCO INC. (JP) | 2011-07-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120070409-A1 | TETRACYCLIC FUSED HETEROCYCLIC COMPOUND AND USE THEREOF AS HCV POLYMERASE INHIBITOR | POLI, TERT, ZC3HAV1 | PRMT5 1658/4885WDR77 2313/4885IDO1 3408/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.